LEOBENDORF, Austria, April 8 — Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis.
A strategic return built on proven heritage
With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering.
Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history.
The reintroduction of Synocrom™ also builds on Croma-Pharma’s long-standing expertise in the development and manufacturing of hyaluronic acid prefilled syringes and reflects the company’s commitment to providing reliable, high-quality solutions for everyday clinical practice.
Hyaluronic acid in knee osteoarthritis
In clinical practice, hyaluronic acid injections are widely used in the treatment of knee osteoarthritis. As a naturally occurring component of synovial fluid, hyaluronic acid contributes to joint lubrication and function and may help alleviate symptoms associated with degenerative joint changes.
Synocrom™ at a glance
- MDR-certified: Synocrom™ is MDR-certified and complies with stringent EU regulatory requirements, supporting safe, controlled and standardized use in the knee osteoarthritis
- Biologically derived hyaluronic acid
- Clinically established: three decades of use in clinical practice
- Favourable tolerability profile: established through routine clinical use
Available from May 2026
Synocrom™ will be available to healthcare professionals in the EU and Switzerland from May 2026. Its return underlines Croma-Pharma’s ambition to build a focused and innovation-driven orthopaedics portfolio while building on the company’s proven expertise and long-standing market heritage.
